Director of Automation and Screening Monte Rosa Therapeutics, Massachusetts, United States
Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) platform enables us to rationally discover and develop selective molecular glue degraders (MGDs) to disease-relevant proteins. We have compiled a growing catalogue of over 1500 proteins identified through our AI-driven approach, containing proteins of diverse protein classes across therapeutic areas, including highly credentialed targets previously deemed undruggable. Monte Rosa uses a proprietary diverse and continuously growing chemical library of drug-like MGDs that are rationally designed based on our expertise in molecular glue anatomy. To discover new MGDs we use a tailored glueomics™ toolbox of highly automated biochemical, biophysical, structural biology, cellular, proteomics and in silico screening tools that connect degrons to MGDs. By leveraging QuEEN and running multiple assays in parallel, we have identified and validated selective MGDs to highly validated and therapeutically relevant but previously undruggable proteins.
